Login

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 33,000 shares of the Company’s common stock (the 'Inducement Awards”) to four new employees pursuant to the Company’s 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee’s start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee’s continued employment on each vesting date).